Physician profile
Jong Min Rho
NPI 1235243999
$54,968.13
in general payments reported to CMS, 2019-2025
21 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,501 · 2020: $19K · 2021: $8,388 · 2022: $18K · 2023: $452 · 2024: $2,296 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,674 · Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,674.00 |
| Food and Beverage | $1,384.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23,777.61 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $13,619.38 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $8,710.56 | 2020 | |
| Biocodex, INC. | $3,400.68 | 2020-2022 | |
| Otter Pharmaceuticals, LLC | $1,674.00 | 2024 | Sympazan |
| Dr.Reddy'S Laboratories,INC. | $1,000.00 | 2022 | |
| Ucb, INC. | $534.68 | 2023-2025 | Fintepla, Briviact |
| Neurelis, INC. | $518.68 | 2020-2025 | Valtoco |
| Sk Life Science, INC. | $487.35 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $413.20 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $349.39 | 2019-2022 | |
| Livanova USA, INC. | $179.06 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $61.49 | 2019-2023 | Brineura |
| Greenwich Biosciences, INC. | $51.78 | 2020 | |
| Ptc Therapeutics, INC. | $44.51 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $42.43 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $24.19 | 2023 | Daybue |
| Catalyst Pharmaceuticals, INC. | $24.01 | 2024 | |
| Azurity Pharmaceuticals, INC. | $21.15 | 2023 | Eprontia |
| Csl Behring | $18.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jong Rho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.